Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera
| Products/Services Used |
Details |
Operation |
| Recombinant Proteins |
SARS-CoV-2 surrogate virus neutralization test kits were obtained from GenScript, Inc., NJ, USA, and the tests were carried out according to the manufacturer’s instructions. |
Get A Quote |
Surrogate neutralization assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be done without biosafety level 3 containment and in multiple species are desirable. We evaluate a recently developed surrogate virus neutralization test (sVNT) in comparison to 90% plaque reduction neutralization tests (PRNT) in human, canine, cat, and hamster sera. With PRNT as the reference, sVNT had sensitivity of 98.9% and specificity of 98.8%. Using a panel of immune sera corresponding to other coronaviruses, we confirm the lack of cross-reactivity to other coronaviruses in SARS-CoV-2 sVNT and PRNT, except for cross-reactivity to SARS-CoV-1 in sVNT.
Surrogate neutralization assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be done without biosafety level 3 containment and in multiple species are desirable. We evaluate a recently developed surrogate virus neutralization test (sVNT) in comparison to 90% plaque reduction neutralization tests (PRNT) in human, canine, cat, and hamster sera. With PRNT as the reference, sVNT had sensitivity of 98.9% and specificity of 98.8%. Using a panel of immune sera corresponding to other coronaviruses, we confirm the lack of cross-reactivity to other coronaviruses in SARS-CoV-2 sVNT and PRNT, except for cross-reactivity to SARS-CoV-1 in sVNT.
COVID-19, SARS coronavirus 2, SARS-CoV-2, animal, antibody, canine, cat, hamster, human, neutralization, seroepidemiology, serology, surrogate virus neutralization
